価格
  1. 米国企業
  2. INVO Fertility, Inc.
  3. Raw

INVO Fertility, Inc.【IVF】

時価総額
$21.5万
PER
生殖医療向け医療機器とARTサービスの新興企業。INVOcellを核とする子宮内培養デバイスとINVOセンターを展開。2024年10月11日の合併、2023年8月10日の買収、2025年3月18日の逆株式分割を実施。米国中心に展開。
株価業績
サマリーテーブルに戻る
2015年
12月31日		2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日		2024年
12月31日
Net loss-4,959,247-2,124,252-702,163-3,076,091-2,167,544-8,347,316-6,654,940-10,892,511-8,034,612-9
Non-cash stock compensation issued for services91,318--246,000150,862--287,4501
Non-cash stock compensation issued to directors and/or employees----17,750465,140360,153484,80756,936153
Fair value of stock options issued to employees--------1342,728
Non-cash compensation for services-------120,000180,000180,000
Amortization of discount on notes payable-1215,132366,126337,4132152,644720,128622,283
Reserve on other assets---------498,592
Gain (loss) from equity method joint ventures---------60,2709,045
Impairment from equity method joint ventures---------89,794-
Loss from debt extinguishment-4,332,155--40,869--93,750-159,126--163,278-40,491
Loss on disposal of fixed assets----------511,663
Gain on lease termination---------94,551
Depreciation and amortization5,6331,8782,8105,19010,78811,91727,76077,301200,894919,603
Accounts receivable---139,202-218,34114,14128,77126,67963,40134,331
Inventory2,96519,790-26,331-15,36657,874163,98522,401-905-44,743
Prepaid expenses and other current assets-10,98052,070-200,596-53,544-38,210124,811-92,550432,093163,761
Equity investments----------4,534
Accounts payable and accrued expenses----377,814-200,298-42,603114,495904,060924,6781
Accrued compensation388,800486,000378,800241,299-1,410,077134,30954,363364,573-224,011274,665
Deferred revenue---18,8954-714,286-3,565,529113,976288,893193,590
Other current liabilities---------226,568-
Leasehold liability--------221,99285,19125,869
Accrued interest------20,9211,556121,864166,772
Deferred tax liabilities----433--810-1,949-
Net cash used in operating activities-151,622-323,900-181,270-652,9711-4,775,148-6,029,914-6,603,319-4,755,054-2,974,400
Payments to acquire property, plant, and equipment-15,700-19,40064,83949,261415,71010,785444,722183,703
Proceeds from sale of fixed assets---------75,590
Cash acquired in acquisition---------472,008
Investment in joint ventures-----98,084----
Payment for acquisitions--------2-
Net cash used in investing activities--15,700--19,400-114,706-187,254-2,153,512-81,217-2,494,879363,895
Proceeds from notes payable-----3-100,00031
Proceeds from notes payable – related parties-------700,000100,000-
Proceeds from the sale of common stock, net of offering costs645,000-54,62547,000-114060
Proceeds from the sale of preferred stock---------2
Proceeds from warrant exercise------123,562-23,051900,611
Proceeds from option exercise--------2,375-
Principal payments on notes payable----131,722770,000250,000-1934,419
Net cash provided by financing activities625,000-54,625858,855-229,465144173
Increase in cash and cash equivalents-------4,412,889-5,594,736142,289508,972
Interest------52,603-9,640214,742
Taxes------3,307800--
Fair value of preferred stock issued for acquisition ---------25
Common stock issued upon conversion notes payable and accrued interest---------387,033
Deemed dividend---------250,635
Fair value of warrants issued with debt--------490,668188,755
Fair value of common stock issued with debt--------56,314-
Fair value of shares issued for settlement of liability---387,000-8,660--65,198-
Initial ROU asset and lease liability--------4-
Fair value of Series B preferred shares issued in exchange for shares of NAYA common stock--------2-